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To date, data on pituitary adenomas in MEN type 1 (MEN1)
still have to be evaluated. We analyzed the data of a large
series of 324 MEN1 patients from a French and Belgian mul-
ticenter study. Data on pituitary disease were compared with
those from 110 non-MEN1 patients with pituitary adenomas,
matched for age, year of diagnosis, and follow-up period. Ge-
netic analysis of the MEN1 gene was performed in 197 of the
MEN1 patients. In our MEN1 series, pituitary disease oc-
curred in 136 of 324 (42%), less frequently than hyperpara-
thyroidism (95%, P < 0.001) and endocrine enteropancreatic
tumors (54%, P < 0.01). Mean age of onset of pituitary tumors
was 38.0  15.3 yr (range, 12–83 yr). Pituitary disease was
associated with hyperparathyroidism in 90% of cases, with
enteropancreatic tumors in 47%, with adrenal tumors in 16%,
and with thoracic neuroendocrine tumors in 4%. Pituitary
disease was the initial lesion of MEN1 in 17% of all MEN1
patients. MEN1 pituitary adenomas were significantly more
frequent in women than in men (50% vs. 31%, P < 0.001). Among
the 136 pituitary adenomas, there were 85 prolactinomas and
12 GH-secreting, 6 ACTH-secreting, 13 cosecreting, and 20
nonsecreting tumors. Eighty-five percent of MEN1-related pi-
tuitary lesions were macroadenomas (vs. 42% in non-MEN1
patients, P < 0.001), including 32% of invasive cases. Among
secreting adenomas, hormonal hypersecretion was normal-
ized, after treatment, in only 42% (vs. 90% in non-MEN1 pa-
tients, P < 0.001), with a median follow-up of 11.4 yr. No cor-
relation was found between the type of MEN1 germ-line
mutation and the presence or absence of pituitary adenoma.
Our study, based on a large group of MEN1 patients, shows
that pituitary adenomas occur in 42% of the cases and are
characterized by a larger size and a more aggressive presen-
tation than without MEN1. (J Clin Endocrinol Metab 87:
457–465, 2002)
MULTIPLE ENDOCRINE NEOPLASIA type 1 (MEN1)is an inherited disease predisposing to primary hy-
perparathyroidism, endocrine enteropancreatic tumors, pi-
tuitary adenomas, adrenocortical and thymic/bronchial neu-
roendocrine tumors (1–4). Most cases occur with a familial
history of MEN1, but sporadic cases of MEN1 are now fre-
quently encountered. MEN1 is related to mutations in MEN1,
an approximately 10-kb gene encoding menin, localized to
chromosome 11q13 (5–7). The reported prevalence of pitu-
itary adenomas in MEN1 is between 15% and 50% (4, 8–14).
This wide range of prevalence values might be related to
differences in technical procedures of the different studies
and mostly limited number of patients included in each of
them (9–11). Moreover, results of prior studies based on
single large MEN1 families require confirmation (2, 13). To
date, very little is known about the size, the outcome, and the
response to therapy of MEN1-related pituitary adenomas.
Thus, to get further insight into pituitary disease in MEN1,
we analyzed the data on pituitary adenomas, in a very large
group of 324 patients with MEN1 from a French-Belgian
multicenter clinical network, the GENEM (Groupe d’Etude
des Ne´oplasies Endocriniennes Multiples) (15, 16). The aim
of our study was to clarify data on pituitary disease in MEN1.
Subjects and Methods
Patients
We analyzed the 324 MEN1 cases collected through the GENEM
registry and belonging to 22 distinct clinical centers in France and Bel-
gium. The diagnosis of MEN1 was assessed in patients presenting at least
2 out of 3 major MEN1 lesions (hyperparathyroidism, endocrine entero-
pancreatic, or anterior pituitary tumors), including both those with and
without MEN1 germline mutation. Diagnosis of MEN1 was also assessed
in patients with a unique major MEN1 lesion and sharing MEN1 germline
mutations. Among the 324 MEN1 cases collected in our registry, a genetic
diagnosis was performed in 197 patients (167 familial cases from 62 families
and 30 from sporadic cases, representing 92 probands) and in related cases
of their family, by heteroduplex (HD) analysis of MEN1 exons and introns
and further sequencing of abnormal sequences by HD analysis. When HD
analysis was negative, the full MEN1 sequence was analyzed as previously
described (15). Families with a common ancestor were considered as a
single family. Most of the mutations identified in the French series of MEN1
patients were reported in the mutation database included in the GENEM
website (http://rockefeller1.univ-lyon1.fr/GENEM/new/database.html
or http://umd2.necker.fr: 2006/) based on UMD software (17). All known
affected members of each family were included. The study was approved
by the ethics committee of Lyon University Hospital, and genetic studies
have been performed after informed consent of each patient, according to
French laws.
Abbreviations: GENEM, Groupe d’Etude des Ne´oplasies Endocrini-
ennes Multiples; HD, heteroduplex; MEN1, MEN type 1.
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Epidemiological methods
For each patient, data on the multiple endocrine neoplasia were
recorded on a file including 164 items. When data were missing or
considered as imprecise, an additional query form was sent to the
physician in charge of the patient. Age of onset for a feature was the age
at the time of diagnosis for this feature. The diagnosis of pituitary lesion
was made on radiological data. Diagnosis of secreting pituitary ade-
noma was made on increased plasma levels of pituitary hormones (PRL,
GH, ACTH). Histopathological data were obtained in 50 patients
(among the 61 subjects who underwent pituitary surgery); and in 42 of
them, immunohistochemistry data were available. Pituitary adenomas
were classified according to their size, using the Hardy classification
(18). Tumors were classified as microadenomas (grade I) when less than
10 mm in diameter, and as macroadenomas (grades II, III, and IV) when
equal or greater than 10 mm in diameter. Grade III (local invasion) and
Grade IV (diffuse invasion) macroadenomas were considered as inva-
sive tumors (18).
Control group
Data obtained in MEN 1 patients were compared with those from 110
non-MEN1 patients with pituitary adenomas. These control subjects
were randomly selected among a list of patients followed for non-MEN1
pituitary tumors in the different endocrinology departments of the
GENEM network. The random selection of the controls matched for age,
year of diagnosis, and follow-up period was performed with software
from SPSS, Inc., Chicago, IL. Each control subject had no other endocrine
lesion than the pituitary tumor and no family history of multiple en-
docrine neoplasia. No control subject had MEN1 mutation testing.
Statistical methods
Results are expressed as mean  sd. For quantitative data, compar-
isons were made by using the t test and ANOVA when comparing two
or several groups of patients, respectively. For qualitative data, com-
parisons between groups were based on the chi-square test. Logistic
regression analysis was performed using the SPSS, Inc. software. Odds
ratio ranges are given with 95% confidence limit.
Results
Frequency, age, and sex distribution of pituitary disease
in MEN1
The distribution of the different endocrine lesions, among
the 324 MEN1 patients, is shown in Fig. 1. Among the 324
MEN1 patients, 136 (42%) had pituitary adenomas and 174
(54%) presented endocrine enteropancreatic tumors. Most
MEN1 patients (308) were affected by hyperparathyroidism
(95%). Adrenal tumors were found in 54 patients (17%), and
thymic or bronchial neuroendocrine tumors in 25 patients
(8%). The types of enteropancreatic tumors were not differ-
ent between MEN1 patients with or without pituitary dis-
ease. The mean age of onset of pituitary disease (38.0  15.3
yr) was not significantly different from that of hyperpara-
thyroidism (39.4  14.1 yr) or enteropancreatic lesions
(40.8 14.0 yr). The age-related penetrance curve of pituitary
adenomas in MEN1 is shown in Fig. 2A. The age of onset of
pituitary adenomas ranged between 12–83 yr. Twenty five
percent of pituitary adenomas were diagnosed before the age
of 26 yr, and 75% before the age of 46 yr. Among the 136
pituitary adenomas, only 6 had an isolated pituitary lesion.
Pituitary adenomas were significantly more frequent in
women than in men (50% vs. 31%, P  0.001).
FIG. 1. Distribution of the main endo-
crine lesions (hyperparathyroidism, en-
docrine enteropancreatic tumors, and
pituitary disease) among the 324 MEN1
patients. For each endocrine lesion, the
number of cases and the percentage of
the affected subjects among the total
MEN1 patients are given [308 patients
with hyperparathyroidism, 174 with
endocrine enteropancreatic tumors,
136 with pituitary adenomas, 54 with
adrenal tumors, and 25 with neuroen-
docrine tumors (thymic or bronchial)].
Adrenal and neuroendocrine tumors
are not in the figure. Among the 54 ad-
renal tumors, 8 are associated with
parathyroid adenoma (PTH) alone, 21
are associated with both PTH entero-
pancreatic tumor (PAN), 2 with both
PTH pituitary adenoma (PIT), 2 with
both PAN  PIT, 16 with PTH  PAN
 PIT, 3 with PTH  PAN  neuroen-
docrine tumor (NEUR), and 2 with PTH
 PAN  PIT  NEUR. Among the 25
neuroendocrine tumors, 2 are isolated,
2 are associated with PTH alone, 11 are
associated with both PTH  PAN, 1
with both PTH PIT, 1 with both PTH
 adrenal tumor (ADR), 3 with PTH 
PANPIT, 3 with PTHPANADR,
and 2 with PTH  PAN  PIT  ADR.
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Occurrence of pituitary disease in the course of MEN1
Among the 136 MEN1 patients with pituitary disease,
pituitary adenoma was the initial manifestation of MEN1 in
56 cases (17% of all MEN1 patients). Thirty-seven of the 136
patients with pituitary disease had concomitantly diagnosis
of pituitary adenoma and another endocrine lesion. The
mean age of the patients with pituitary disease as initial
manifestation of MEN1 (33.9  14.0 yr) was significantly
younger than that of patients showing first an endocrine
enteropancreatic tumor (41.6  14.0 yr, P  0.01) (Table 1).
The mean delay between the initial and the subsequent
MEN1 endocrine lesion was significantly longer when pitu-
itary disease was the initial MEN1 manifestation (9.0  8.1
yr) than when enteropancreatic tumor (4.1  4.0 yr) or hy-
perparathyroidism (5.2 5.1 yr) were the initial presentation
of MEN1 (Table 1). The proportion of MEN1 patients with
pituitary disease was 40% before 1984, 49% between 1984 and
1994, and 34% after 1994. Prevalence of pituitary disease was
significantly different among these 3 periods (P 0.05); but,
as shown in Fig. 2B, the age-related penetrance curve of
pituitary disease was not different among the 3 periods. The
diagnosis of MEN1 before the age of 25 yr was significantly
more frequent after 1994 (26%) than before 1994 (11%)
(P  0.01).
FIG. 2. A, Age-related penetrance curve of pitu-
itary adenomas in MEN1 and age-related pen-
etrance curve of MEN1 (age of MEN1 diagnosis).
B, Age-related penetrance curve of pituitary ad-
enomas in MEN1 during 3 periods: before 1984,
between 1984 and 1994, and after 1994.
TABLE 1. Mean age (in years) of the initial MEN1 endocrine lesion and mean delay (in years) between the initial and the subsequent
MEN1 endocrine lesion for each main endocrine lesion (hyperparathyroidism, enteropancreatic tumor, or pituitary disease) as unique












MEN1 (n  56)
Age of the initial MEN1 endocrine
lesion (yr)
35.0  14.4a 41.6  14.0a,b 33.9  14.0b
Delay between the initial and the
subsequent MEN1 endocrine
lesion (yr)
5.2  5.1c 4.1  4.0d 9.0  8.1c,d
a Hyperparathyroidism vs. pancreatic tumor, P  0.01.
b Pituitary disease vs. pancreatic tumor, P  0.01.
c Pituitary disease vs. hyperparathyroidism, P  0.001.
d Pituitary disease vs. pancreatic tumor, P  0.001.
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Pituitary disease in familial and sporadic MEN1
Among the 136 MEN1 patients with pituitary disease, 75
were familial and 61 sporadic. Prevalence of pituitary disease
was significantly higher in sporadic MEN1 patients than in
familial MEN1 subjects (59% vs. 34%, P  0.001). However,
among MEN1 patients with at least 2 organs affected, prev-
alence of pituitary adenomas between sporadic (59%) and
familial (47%) cases was not statistically different.
Search for criteria predisposing to pituitary disease
Factors related to the risk of occurrence of pituitary ade-
noma in MEN1 were searched by multivariate analysis using
a multiple logistic regression model. Criteria included were
sex, age at time of diagnosis, sporadic or familial case, time
of MEN1 diagnosis, onset of death during the follow-up
period, and presence of adrenal and/or thymic/bronchial
neuroendocrine tumors. Sporadic occurrence of MEN1 [odds
ratio: 1.67 (range, 1.29–2.17), P 0.001] and female sex [odds
ratio: 1.42 (range, 1.11–1.82), P  0.01] were independently
associated with an increased prevalence of pituitary disease,
whereas other criteria were not. When the multivariate anal-
ysis was performed in MEN1 patients with at least two
organs affected, only the female sex was associated with
prevalence of pituitary adenoma in MEN1 [odds ratio: 1.50
(range, 1.30–1.71), P  0.01].
Type of pituitary adenomas
Among the 136 pituitary adenomas, 85 were prolactino-
mas (62%), 12 were GH-secreting adenomas (9%), 6 pro-
duced ACTH (4%), and 13 (5 PRLGH; 2 PRL FSH; 4 PRL
 ACTH, 1 PRL  -subunit, and 1 GH  -subunit) were
cosecreting adenomas (10%) (Table 2). Twenty of the 136
cases were nonsecreting (15%); and in 2 of 15 nonsecreting
adenomas histologically examined, immunohistochemistry
was positive for LH and FSH. Eighty-six patients presented
clinical manifestations related to pituitary hypersecretion
(Table 2). Thirty-nine patients (29%) had clinical manifesta-
tions related to the size of the pituitary adenoma (headache
alone in 5 patients, visual defects alone in 22, and both in 12).
Mean age of patients with prolactinomas was significantly
younger than that of other types of pituitary adenomas
(35.1 14.8 vs. 43.8 14.4 yr, P 0.001). No differences were
shown among the different types of pituitary adenomas by
comparing sex distribution, sporadic and familial MEN1,
and the time of occurrence in the course of MEN1. As far as
prolactinomas were concerned, there were no significant dif-
ferences between men and women for age at diagnosis, size
of the adenoma, and time of occurrence in the course of
MEN1.
Size of pituitary adenomas
Among the 136 pituitary lesions, 19 were microadenomas
(14%), and 116 were macroadenomas (85%), including 43
invasive macroadenomas (grades III and IV from Hardy
classification). All the GH and nonsecreting tumors were
macroadenomas (including, respectively, 8 and 10 invasive
tumors). Among the 85 prolactinomas, 71 were macroad-
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ACTH-secreting adenomas, 3 were macroadenomas (50%),
including 1 invasive tumor. Among the 13 cosecreting ade-
nomas, 10 were macroadenomas (77%), including 4 invasive
tumors (Table 2). The frequency of macroadenomas was not
different between familial and sporadic MEN1 and among
age-quartiles. The proportion of pituitary microadenomas
was not statistically different between patients diagnosed
before 1994 (14%) and those diagnosed after 1994 (16%).
Outcome of pituitary adenomas
Various therapeutic strategies used in our series are shown
in Table 3. Each patient was treated optimally in 1 of the 22
multidisciplinary centers from the GENEM sharing similar
updated protocols. The median follow-up period for all the
MEN1 pituitary adenomas was 11.4 yr (range, 0–47.9 yr).
During this follow-up period, death occurred in 4 patients
and was directly related to the pituitary lesion in only 1
patient. As far as the 116 patients with pituitary secreting
adenomas were concerned, normalization of the pituitary
hypersecretion occurred, on treatment, in 49 patients (42%),
hormonal hypersecretion persisted in 53 (46%), and hypo-
pituitarism developed after treatment in 8 patients (7%). No
data concerning the outcome were available for 6 of the
patients (Table 3). Normalization of pituitary hypersecretion
occurred in 56% of patients with grade I or II tumor size and
only in 33% of patients with grade III or IV tumor size (P 
0.05). Among the 85 prolactinomas, plasma PRL levels were
normalized in only 37 patients (44%).
Comparison with non-MEN1 pituitary adenomas
Data obtained in MEN 1 patients were compared with
those from 110 non-MEN1 patients with pituitary adenomas
matched for age, year of diagnosis, and follow-up period. As
shown in Table 4, the distribution of the types of pituitary
adenomas was not significantly different between the 2
groups. The frequency of macroadenomas was significantly
higher in MEN1 patients than in non-MEN1 subjects (85% vs.
42%, P 0.001). Clinical manifestations related to the size of
the pituitary adenoma (headache, visual defects) were sig-
nificantly more frequent in MEN1 patients than in non-
MEN1 subjects (29% vs. 14%, P 0.01). As far as the secreting
pituitary adenomas were concerned, normalization of pitu-
itary hypersecretion was much less frequent in MEN1 pa-
tients than in non-MEN1 subjects (42% vs. 90%, P  0.001)
(Table 4). Macroprolactinomas were more frequent in MEN1
patients than in non-MEN1 subjects (84% vs. 24%, P 0.001),
and normalization of plasma PRL level was significantly less
frequent in MEN1 patients than in non-MEN1 subjects (44%
vs. 90%, P  0.001).
Genetic analysis
Among the 197 MEN1 patients (167 familial cases and 30
sporadic cases) who had genetic analysis of the MEN1 gene,
germline mutations of the MEN1 gene were found in 150, and
a large MEN1 germline deletion in 25 patients from a single
family (Lespinasse et al., submitted). In 22 patients, we did
TABLE 3. Treatment of the pituitary adenomas in MEN1 patients and outcome
n















PRL 85 29 8 52 3 12.9 37 37 6 5
GH 12 8 5 3 11.9 6 4 2
ACTH 6 4 1 4 8.9 2 3 0 1
Cosecreting 13 6 1 8 12.9 4 9 0
Nonsecreting 20 17 4 1 8.4 5
TABLE 4. Pituitary adenomas in MEN1 patients and in controls






Age (yr) 38.0  15.3 36.2  14.6 NS
Mean follow-up (yr) 11.1  8.7 10.0  6.3 NS
Type of pituitary adenoma:
PRL n  85 n  68
NS
GH n  12 n  15
ACTH n  6 n  7
Cosecreting n  13 n  2
Nonsecreting n  20 n  18
Clinical signs related to tumor size n  39 (29%) n  15 (14%) P  0.01
Tumor size
Microadenoma n  19 (14%) n  64 (58%) P  0.001
Macroadenoma n  116 (85%) n  46 (42%)
no data: n  1 (1%)
Outcome
Normalization of pituitary hypersecretion n  49 (42%) n  83 (90%) P  0.001
For each qualitative data, the number of patients and the percentage of affected patients in each group (MEN1 patients and controls) are
given. The results of the statistical comparison between the two groups (MEN1 patients and controls) are shown in the last column.
}
}
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not find any MEN1 germline mutations/deletions. A germ-
line mutation/deletion of the MEN1 gene was observed in
63% of the tested sporadic cases and in 93% of the tested
familial cases. The 167 familial cases belonged to 62 different
families. Among these 62 families, a mutation was found in
54 families, a complete deletion in 1 family (with 25 affected
members), and no mutation or deletion in 7 families. Nine
families sharing the same mutation [respectively, 2 with
359del4 (exon 2), 2 with R98 (exon 2), 2 with R460 (exon
10), and 3 with 1650insC/G (exon 10)] were shown to be
unrelated, using both 11q13 haplotype analysis and ascen-
dant genealogical evaluation, by techniques which have been
previously described (15). The mutations observed in our
MEN1 patients and the relative penetrance of pituitary dis-
ease for each of them are shown in Fig. 3. No obvious gen-
otype-phenotype correlation was observed, and we consid-
ered that no specific types and/or locations of mutations
might be significantly correlated with the risk of occurrence
of pituitary adenoma in our MEN1 series. No differences
were observed, between the 197 MEN1 patients for whom
genetic testing has been performed and the 127 patients in
which genetic testing was not undertaken, for the frequency
of pituitary disease (42% vs. 43%), the sex ratio, the distri-
bution of endocrine lesion, the rate of pituitary adenomas as
initial lesion of MEN1, the size of the pituitary adenomas, the
treatment of pituitary adenomas, and the outcome.
Discussion
MEN1 has an estimated prevalence of 0.02–0.2 per 1000
(8). Data on pituitary lesions in MEN1 are uncommon to date,
and we consider the present study as the largest one reported
so far. In our work including patients from 22 different mul-
tidisciplinary centers from the GENEM, in France and Bel-
FIG. 3. Detailed overview of MEN1 germline mutations ( 1 complete gene deletion) and pituitary disease expression found in 156 patients
from 55 unrelated MEN1 families and 19 patients with a priori sporadic MEN1 disease. This represents a total number of 68 distinct mutations
(49 observed in familial and 19 in sporadic cases). Clear boxes and the numeric numbers inside represent exonic sequences. Intronic regions
are summarized by a dotted line. Black boxes (exon 1 and a part of exon 10) represent untranslated regions of the gene. Mutations are
approximately localized along the gene and shown using a comprehensive nomenclature system, including reference letters for amino acids (41).
For instance, 177delT, a frameshift mutation, indicates deletion of T after nucleotide 177 in exon 2. R98, a nonsense mutation, indicates a
premature translation stop at codon 98 by disruption of the arginine (R) coding triplet. For nonsense mutations, the premature translations
stop are directly drawn on the coding sequence. Missense mutations are symbolized using the amino acid reference letter and position of the
affected codon. In-frame deletions are shown in italic bold characters. Intronic and/or splice site mutations are indicated by an arrow under
the gene sequence. ATG and TGA represent menin translation the codon and termination codon, respectively. DEL (MEN1) indicates the full
deletion, found in a large MEN1 family, affecting the whole MEN1 coding sequence and adjacent regions (Lespinasse et al., submitted for
publication). The first number in parentheses, in bold, indicates the number of patients affected by pituitary disease for each mutations. The
second number shows the total number of MEN1 patients in the family sharing the mutation. For instance, the family with a germline 337delC
MEN1 mutation is characterized by 1 patient with pituitary lesions among a total of 3 affected, symbolized by (1/3). Last, recurrent mutations
are designed by underlined bold characters. Nine families showed 4 common mutations, respectively (2 with 359del4, 2 with R98, 2 with R460,
and 3 with 1650insC/G). For these recurrent mutations, the first number in parentheses indicates the total number of patients affected by
pituitary disease, and the second number indicates the total number of MEN1 patients in all unrelated families sharing the common mutation.
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gium, one would expect a reduced recruitment bias, com-
pared with monocentric reports (10, 11, 13, 19, 20). Thus, our
extensive, multicenter, and multidisciplinary study gives the
opportunity to obtain representative and indicative infor-
mation on pituitary disease in MEN1. Moreover, we have
been able to compare the data obtained in MEN 1 patients
with those from 110 non-MEN1 patients with pituitary ad-
enomas, matched for age, year of diagnosis, and follow-up
period. On the basis of several reports that have shown that
MEN1 germline mutation testing was not useful in isolated
sporadic pituitary adenomas (21–23), no control subject had
MEN1 mutation testing. However, each control subject had
no other endocrine lesion than the pituitary tumor at the time
of diagnosis, as during the follow-up period, and no family
history of multiple endocrine neoplasia, attesting that control
subjects were non-MEN1 patients.
Prevalence of pituitary disease among our MEN1 patients
was 42%, and this is equivalent or higher than frequencies
reported by O’Brien (43%) (20), O¨berg (42%) (9), Burgess
(18%) (13), Trump (29.5%) (4), and Skogseid (20%) (11) and
slightly lower than the prevalence rate reported by Marx (14).
However, prevalence of pituitary lesions reported by nec-
ropsy studies in MEN1 (65%) suggests that diagnosis of
pituitary adenoma may be missed in some patients during
the lifetime course of the disease (24). Pituitary disease was
the first manifestation of MEN1 in 17% of our patients, which
is in agreement with a previous report (25). The mean delay
between the initial and the subsequent MEN1 endocrine
lesion is significantly longer when pituitary disease is the
initial MEN1 manifestation than when enteropancreatic tu-
mor or hyperparathyroidism is the initial presentation of
MEN1. This could be attributable, in part, to the younger age
of the patients with pituitary disease as initial manifestation
of MEN1, but also to a less frequent consideration of MEN1
diagnosis in patients with pituitary adenomas than in pa-
tients with endocrine enteropancreatic tumors or hyper-
parathyroidism.
We show that MEN1-related pituitary disease may occur
at all ages from 12–83 yr. Indeed, pituitary adenomas may
be present at an early age, and macroadenomas are as fre-
quent in young as in old patients. This is in agreement with
a recent report of an aggressive pituitary adenoma in a 5-yr-
old boy with familial MEN1 (26). Previous studies suggested
that the onset of pituitary disease in MEN1 could not occur
after the age of 60 yr (3, 9–11). Our results do not support this
view and are in agreement with the data reported by Trump
et al. (4), who noted that the rate of pituitary adenoma di-
agnosis in MEN1 was not different below and above 40 yr.
Prevalence of pituitary disease among our MEN1 patients
was lower before 1984 than during the 1984–1994 period.
This increase is likely to be attributable to the wider use of
computed tomography and magnetic resonance imaging.
After 1994, the pituitary adenoma diagnosis rate is found to
be less important. Diagnosis of MEN1 is performed earlier,
since 1994, as a consequence of the generalization of genetic
analyses. Thus, the higher rate of young MEN1 patients after
1994 is likely to be the main reason for the reduced pituitary
adenoma diagnosis rate during this last period of our study.
Indeed, as suspected on the age-related penetrance curve, the
younger the patients are, the lower the risk to have a diag-
nosed pituitary adenoma.
The increased female-to-male ratio in MEN1 patients with
pituitary adenoma is equivalent to what has been observed
for pituitary adenomas in non-MEN1 patients (27). The in-
fluence of sex on the prevalence of pituitary disease in MEN1
is not confounded by other factors, as shown in the multi-
variate analysis. This increased prevalence of pituitary ad-
enomas in women is not explained. However, a role of es-
trogens could be considered, because there is experimental
evidence that estrogens can amplify tumor growth-promot-
ing factors in pituitary cell lines (28). As suggested by our
analysis limited to MEN1 patients with at least two endocrine
lesions, the higher frequency of pituitary adenomas in spo-
radic than familial cases, observed in the whole MEN1 pop-
ulation, is likely to be attributable to the bias that sporadic
MEN1 cases must, according to the definition, have two or
more organs affected to be diagnosed.
Pituitary adenoma in our MEN1 patients was not associ-
ated with a specific type of MEN1 gene mutation. Our results
confirm previous studies, which did not show any geno-
type/phenotype correlation in MEN1 (15, 29–31).
Prolactinomas represent about two thirds of the pituitary
adenomas in our MEN1 patients and may be considered as
the most frequent pituitary lesion in MEN1, confirming pre-
viously reported data obtained in a limited number of pa-
tients and families (9, 10, 13, 32). According to our results, the
high frequency (85%) of pituitary macroadenomas seems to
be an important feature of pituitary disease in MEN1. Be-
cause most of our MEN1 patients were symptomatic, we
cannot completely exclude the possibility that some asymp-
tomatic and small pituitary tumors have been missed in some
families. However, after 1994, despite an earlier age of MEN1
diagnosis and a more developed MEN1 family screening, the
proportion of pituitary microadenomas was not different
than before 1994, suggesting that the number of missed
asymptomatic and small pituitary tumors is likely to be very
small. This prevalence of macroadenomas is significantly
higher than in our control non-MEN 1 group. Our data point
out the high prevalence (84%) of macroadenomas in MEN1-
related prolactinomas, compared with those observed in
non-MEN1 patients, from our study (24%), as from the lit-
erature (30%) (33, 34). The increased prevalence of invasive
macroadenomas in MEN1 suggests that pituitary tumors
might be more proliferative in MEN1 patients than in non-
MEN1 patients.
In previous studies, prolactinomas in MEN1 have been
considered comparable, in both clinical behavior and re-
sponse to treatment, to those occurring in non-MEN1 pa-
tients (10, 35). However, our data, as those of Burgess (36),
suggest a more aggressive natural history of prolactinomas
in MEN1. Indeed, we show that prolactinomas in MEN1 are
characterized by a larger size but also by a worse response
to therapy. Thus, our data suggest that prolactinomas in
MEN1 may be more aggressive than those occurring in non-
MEN1 patients.
In our series, treatment of pituitary adenomas had a higher
success rate at earlier tumor stages. Moreover, several studies
have shown that the control of pituitary secreting adenomas
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is more frequent in microadenomas (80–90%) than in mac-
roadenomas (60–75%) (37–40). Thus, it seems reasonable to
recommend earlier diagnosis of pituitary adenomas in
MEN1, to increase the rate of control of pituitary secreting
adenomas.
In conclusion, pituitary disease is a major component of
MEN1; and we show, based on a large population study, that
it occurs in 42% of the MEN1 patients. The majority of pi-
tuitary adenomas are prolactinomas. Compared with pitu-
itary adenomas in the non-MEN1 population, pituitary le-
sions in MEN1 are characterized by a higher frequency of
macroadenomas and a worse response to treatment. This
suggests that pituitary adenomas in MEN1 may be more
aggressive than those occurring in the non-MEN1 patients.
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